CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Accelerating Early-Stage Drug Development

Safwan Kezbor, M.D. Medical Director, Clinical...

Medical Affairs Takes Centre Stage

Dr Sarah Tregenza PhD BSc(Hons), APAC Oncology...

A proposal for a new strategy in oncology...

Stefano Ferrara, Director, Clinical Science, BeiGene

Analytical Considerations for Combination...

Jennifer L. Riter, Sr. Director, Business and...

Analytics as a Competitive Advantage Takes...

Matt Southwick, Executive Director Clinical Systems...

How Integrating IIoT with LIMS Can Enhance...

Aviana Rios, Director, Digital Technology, Viatris

How Allogeneic Stem Cell Therapies Can...

Gil Carrasquinho, VP Head of Cell Therapy, Santen

Optimizing Clinical Trials: Leveraging...

Craig Herron, Managing Director, iSelect Fund

Accelerating Early-Stage Drug Development

Safwan Kezbor, M.D. Medical Director, Clinical...

Medical Affairs Takes Centre Stage

Dr Sarah Tregenza PhD BSc(Hons), APAC Oncology...

A proposal for a new strategy in oncology...

Stefano Ferrara, Director, Clinical Science, BeiGene

Analytical Considerations for Combination...

Jennifer L. Riter, Sr. Director, Business and...

Analytics as a Competitive Advantage Takes...

Matt Southwick, Executive Director Clinical Systems...

How Integrating IIoT with LIMS Can Enhance...

Aviana Rios, Director, Digital Technology, Viatris

How Allogeneic Stem Cell Therapies Can...

Gil Carrasquinho, VP Head of Cell Therapy, Santen

Optimizing Clinical Trials: Leveraging...

Craig Herron, Managing Director, iSelect Fund

From ideation to portfolio program: Innovation vs validation in early drug discovery

Carlos Pedraza, PhD. Director of CNS Biology, Alkermes
Tweet

Selecting a new pharmacological target for drug discovery is one of the hardest jobs in pharma. This assertion while it may be generally accepted, is surely not fully appreciated nor completely understood. It doesn’t help it that there’s not an established method or a stepwise manual for succeeding in such endeavor and the prospects to embarking and resourcing it could be daunting.


How do pharmaceutical companies decide what projects have the best value to pursue from inception all the way up to candidate nomination, IND and beyond? What’s the secret sauce for success in an industry with high attrition rates at all stages of the process of drug discovery and development? Is it possible to achieve a productive balance of novel ideas-technologies and well validated pharmacological targets with a solid progression into clinicaltrial stages? These are important questions that could define the success, and even the survival or demise of small to mid-size companies looking to establish themselves as drug discovery enterprises.


the most difficult part is the conception or ideation stage as it requires, in order to be successful, a significant investment in brain power and intellectual input from the entire value chain

 


With this in mind one could divide the process of new target identification into several stages, all overlapping more or less with each other according to the specific company’s strategic plan: Conception, experimental validation, assay development, MoA characterization, therapeutic proof of concept, IND enabling data generation and early clinical development.Each one of these topics comes with a long list of sub-divisions, milestones, go-no go decision points, iterations, critical path, good-to-haves, timelines, budgets, etc.


Perhaps the most difficult part is the conception or ideation stage as it requires, in order to be successful, a significant investment in brain power and intellectual input from the entire value chain (pre- and clinical). It is a time-consuming exercise where those involved gather information from scientific literature, public or proprietary databases (OMICS, tissue atlas, patents, clinical trials, etc.) and tap into internal and external expertise.With the available data in hand, the group evaluates central aspects of the target at issue.


First and foremost, the biology rationale and the technical feasibility, with the goal of ensuring to the best of the team’s knowledge, that there is enough, convincing evidence of a biological mode of action which can be approached, altered or modulated with a pharmacological entity.If there are sufficient “reasons to believe”, the target will then move forward into the experimental validation and assay development stages.


At this early point is where and when the team struggles between innovation (novel, unvalidated targets)and repetition (programs already attempted by others therefore with certain level of validation). Both options present themselves with the problem of defining and allocating time and resources. Innovation takes time -lots of it-, and continuous investment. Repetition on the other hand, relies in a good part on previous failures, acquired knowledge and experiences and a higher level of confidence in advancement. Both approaches are risky and suffer from high attrition rates. New programs fall often and hard, in most cases before they are official or fully powered. While that’s perfectly appropriate -it’s best to kill a project early and well, with good decision making and supportive data, before it becomes too expensive, burdensome, unviable-, it adds to the challenges of moving an idea forward beyond the concept level.


Thus, the question still stands: What’s the better path to progress an idea, a pharmacological target or a proposal for a project? Innovate and generate your own science (risky, high probability of failure, long term investment) or tap into what the scientific community has already a basic knowledge on? As I hope we have established, there’s not a fool-proof path to success but the answer might be both.


By populating the early discovery pipeline with a variety of new programs including, high risk-high reward, low risk-steady progression, innovative approaches and well validated ones, and something in between, R&D institutions stay competitive and enhance their chances to reach scientific PoC and ultimately the clinic. Ideally, this variety approach will provide a substratum of ideas and targets to resourcefrom, with the potential to die early or to move forward into subsequent stages of the drug discovery process.


Weekly Brief

loading
Top 10 Clinical Laboratory Services Companies – 2022
> <
  • Clinical Laboratory Services 2022

    Top Vendors

    Current Issue
  • Clinical Laboratory Services 2022

    Top Vendors

    Current Issue

Read Also

The Value of New Antibiotics in the Fight Against AMR

Piero Rijli, Corporate Director, Regulatory Activities and Market Access, MENARINI Group

Improving Minimal Residual Disease Detection Using NGS

Steven Henck, Ph.D., Vice President of R&D, Integrated DNA Technologies

Multiomic Preclinical Models to Define the Mechanism of Action

Mitch Sanders, Chief Scientific Officer and EVP of the ProDevLab, at Alira Health

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Sanjay Konagurthu, Senior Director, PDS Global Science and Technology, Thermo Fisher Scientific

What the New EMA Draft "Guideline on Computerised Systems and Electronic Data" Means to Your Systems

Cathlin Shapiro, Director, Technology Quality Assurance, Parexel

Pharmaceutical Tablet Coating - Past, Present and Future

Steve Brown, Senior Director EU and APAC Global Manufacturing Science and Technology, Teva Pharmaceuticals [NYSE: TEVA]

Dynamic Commercial Aspects of Life Sciences

Jim Cooper, Director, Clinical Operations, Moderna

Achieving trial master file quality, timeliness and completeness

Susan K. Maue, Designation : Managing Director PharmaLex
Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://clinical-laboratory-services.lifesciencesreview.com/cxoinsight/from-ideation-to-portfolio-program-innovation-vs-validation-in-early-drug-discovery-nwid-867.html